| Nicholas Baron, PA-C | |
|
6092 Mayfield Rd, Mayfield Heights, OH 44124-3225 | |
| (440) 462-4677 | |
| Not Available |
| Full Name | Nicholas Baron |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 8 Years |
| Location | 6092 Mayfield Rd, Mayfield Heights, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033657028 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 50.004966RX (Ohio) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summa Physicians Inc | 2961303532 | 640 |
News Archive
Researchers have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. These are the results of a study published in Nature Cell Biology on June 20, and led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, Princess Margaret Cancer Center, the University of Toronto, Harvard Medical School and Oxford University.
GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.
In a new study published in the August 16th issue of Developmental Cell, researchers at NYU Langone Medical Center identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.
Abbott today announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures (ischemia-driven target lesion revascularization) and a very low rate of major adverse cardiac events (MACE(1) rate of 2.0 percent) at 30 days.
Integra LifeSciences Holdings Corp will feature the new Integra™ Flow Regulating Valve, Mini, a smaller version of the Integra NPH™ Low Flow Valve, at the 2010 Congress of Neurological Surgeons Annual Meeting in San Francisco, California, October 16-21, 2010. The Integra™ Flow Regulating Valve, Mini is Integra's newest implantable shunt valve used in the management of hydrocephalus and was designed with a lower profile than the Integra NPH™ valve to accommodate various patient populations, particularly patients with thin, fragile skin.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicholas Baron, PA-C 6092 Mayfield Rd, Mayfield Heights, OH 44124-3225 Ph: (440) 462-4677 | Nicholas Baron, PA-C 6092 Mayfield Rd, Mayfield Heights, OH 44124-3225 Ph: (440) 462-4677 |
News Archive
Researchers have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors. These are the results of a study published in Nature Cell Biology on June 20, and led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, Princess Margaret Cancer Center, the University of Toronto, Harvard Medical School and Oxford University.
GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.
In a new study published in the August 16th issue of Developmental Cell, researchers at NYU Langone Medical Center identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.
Abbott today announced positive 30-day results from the first 101 patients enrolled in the second phase of the ABSORB trial. Patients treated with Abbott's bioresorbable vascular scaffold (BVS), under clinical investigation in Europe, demonstrated no cases of blood clots (thrombosis), no need for repeat procedures (ischemia-driven target lesion revascularization) and a very low rate of major adverse cardiac events (MACE(1) rate of 2.0 percent) at 30 days.
Integra LifeSciences Holdings Corp will feature the new Integra™ Flow Regulating Valve, Mini, a smaller version of the Integra NPH™ Low Flow Valve, at the 2010 Congress of Neurological Surgeons Annual Meeting in San Francisco, California, October 16-21, 2010. The Integra™ Flow Regulating Valve, Mini is Integra's newest implantable shunt valve used in the management of hydrocephalus and was designed with a lower profile than the Integra NPH™ valve to accommodate various patient populations, particularly patients with thin, fragile skin.
› Verified 7 days ago
Claire Konys, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 6780 Mayfield Rd, Mayfield Heights, OH 44124 Phone: 216-210-6771 | |
Mr. Heath A Austin, PA-C Physician Assistant Medicare: Medicare Enrolled Practice Location: 6780 Mayfield Rd, Mayfield Heights, OH 44124 Phone: 440-312-4500 | |
Nicole Tatomirovich, Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 5800 Landerbrook Dr Ste 100, Mayfield Heights, OH 44124 Phone: 440-443-0423 Fax: 440-443-0414 | |
Holly Nicole Mariola, Physician Assistant Medicare: Medicare Enrolled Practice Location: 6780 Mayfield Rd, Mayfield Heights, OH 44124 Phone: 440-312-4500 | |
Steven Drellishak, Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 6780 Mayfield Rd, Mayfield Heights, OH 44124 Phone: 440-312-4500 | |
Ms. Marian Rae Barton, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 6092 Mayfield Rd, Mayfield Heights, OH 44124 Phone: 440-462-4677 |